News
EMA launches pilot for breakthrough medical devices in the EU
19+ hour, 47+ min ago (21+ words) Bio World News EMA launches pilot for breakthrough medical devices in the EU...
Axsome's Auvelity cleared for large Alzheimer's agitation market
19+ hour, 47+ min ago (351+ words) Axsome Therapeutics Inc. won U. S. FDA approval for Auvelity, also referred to as AXS-05, to treat Alzheimer's disease agitation (ADA), a condition that affects up to three-quarters of patients, gaining access to a $1 billion-plus market and a clean label that counters…...
Laguna Biotherapeutics" LGNA-100 gains IND clearance
22+ hour, 47+ min ago (62+ words) Laguna Biotherapeutics Inc. has obtained IND clearance from the FDA for its cancer immunotherapeutic LGNA-100 (QUAIL-100). The planned first-in-human phase I study will evaluate LGNA-100 in pediatric and young adult participants with high-risk acute leukemias and myelodysplastic syndromes following "-depleted…...
Quintuple GLP-1 GIPPPAR agonist for obesity and diabetes control
22+ hour, 47+ min ago (108+ words) A new molecule combines the action of two incretins, GLP-1 and GIP, hormones that regulate glucose and appetite, with lanifibranor, a triple agonist of peroxisome proliferator activated receptors (PPAR "//). GLP-1 GIPLani enables targeted delivery of the PPAR agonist to cells…...
Pheon Therapeutics prepares and tests new CDCP1-targeting ADCs
22+ hour, 47+ min ago (19+ words) Bio World News Pheon Therapeutics prepares and tests new CDCP1-targeting ADCs...
Ailux's ALX-006 exerts antitumor activity in preclinical setting
22+ hour, 47+ min ago (21+ words) Bio World News Ailux's ALX-006 exerts antitumor activity in preclinical setting...
Dermatology specialist Leo Pharma makes a $50 M move into gene therapy
19+ hour, 47+ min ago (23+ words) Bio World News Dermatology specialist Leo Pharma makes a $50 M move into gene therapy...
Beone eyes Huahui Health's trispecific HH-160 with $2 B option deal
19+ hour, 47+ min ago (25+ words) Bio World News Beone eyes Huahui Health's trispecific HH-160 with $2 B option deal...
Xenon's azetukalner exceeds expectations in FOS
1+ mon, 3+ week ago (804+ words) Shares of Xenon Pharmaceuticals Inc. soared as the company's top-line readout of the phase III X-Tole2 study testing azetukalner in focal onset seizures (FOS) solidly bested expectations, positioning. .. Xenon's azetukalner exceeds expectations in FOS Shares of Xenon Pharmaceuticals Inc. soared as…...
Worth the wait: Xenon's azetukalner exceeds expectations in FOS
1+ mon, 3+ week ago (69+ words) Any lingering disappointment in the delay for Xenon Pharmaceuticals Inc. s readout of the phase III X-Tole2 study testing azetukalner in focal onset seizures (FOS) appeared thoroughly extinguished as the companys KV7 potassium channel opener yielded better-than-expected data, even besting earlier phase…...